Company profile: NanoViricides
1.1 - Company Overview
Company description
- Provider of nanomedicine-based antiviral therapeutics, developing broad-spectrum candidates including NV-387 (RSV, smallpox, mpox, influenza A), NV-CoV-2 for COVID-19 and potentially long COVID (Phase 1a/1b), NV-CoV-2-R with remdesivir, and NV-HHV-1 for shingles rash, leveraging the TheraCour platform and the HerpeCide program for herpes infections (cold sores, genital ulcers, keratitis).
Products and services
- TheraCour Technology: A nanomedicine platform that engineers antiviral drug products by mimicking host cell receptors to trap and destroy viruses, enabling creation of therapeutics for life-threatening viral infections
- NV-CoV-2: An antiviral drug candidate for treating COVID-19 and potentially long COVID, currently in Phase 1a/1b clinical trials
- NV-387: A broad-spectrum antiviral drug candidate showing effectiveness against RSV, smallpox, mpox, and influenza A, enabling multi-pathogen therapeutic development for severe viral threats
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NanoViricides
Cytovale
HQ: United States
Website
- Description: Provider of early detection diagnostic technologies for immune-mediated diseases, including the IntelliSep Test for rapid sepsis identification with results in under 10 minutes to aid emergency department triage, powered by microfluidics, precision imaging, and machine learning to analyze complex biological data and perform detailed cellular analysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cytovale company profile →
Cempra
HQ: United States
Website
- Description: Provider of medicines for the treatment of bacterial infections and chronic illnesses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cempra company profile →
Mesa Biotech
HQ: United States
Website
- Description: Provider of DNA and RNA molecular testing services and COVID-19 diagnostic products, including the Accula SARS-CoV-2 molecular test and testing kits with high-throughput and rapid tests, controls, combo kits, reagents, and buffers. Based in San Diego, California, with a satellite testing laboratory in Santa Fe, New Mexico.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mesa Biotech company profile →
Protez Pharmaceuticals
HQ: United States
Website
- Description: Provider of differentiated intravenous and oral small molecule antibiotics for difficult-to-treat hospital-based infections, addressing bacterial resistant and chronic or recurrent infections; discovers, develops, and commercializes antibiotic therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Protez Pharmaceuticals company profile →
Artus Biotech
HQ: Germany
Website
- Description: Provider of DNA-based diagnostic kits focused on PCR and real-time PCR, developed, produced, and sold for detection of infectious agents and use in pharmacogenomics and veterinary applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Artus Biotech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NanoViricides
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NanoViricides
2.2 - Growth funds investing in similar companies to NanoViricides
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NanoViricides
4.2 - Public trading comparable groups for NanoViricides
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →